# Cochrane Library

# Jitsumura 2022 (Continued)

Trusted evidence. Informed decisions. Better health.

# Cochrane Database of Systematic Reviews

- Neurologic, neurodevelopmental, or neurodegenerative disorders
- Depression (requiring therapy)
- Obesity (BMI > 35)
- Malignancy
- Use of antibiotics for any indication within past 3 months
- Foreign travel to areas with enteric disease prevalence within 3 months
- High-risk sexual behavior (e.g. sexual contact with anyone with HIV/HTLV/AIDS or hepatitis B/C carrier, men who have sex with men)
- Known exposure to HIV or hepatitis B/C
- Current/previous use of injected drugs or intranasal cocaine
- Tattoos, piercings, cosmetic botulinum toxin (Botox) or permanent makeup within 120 days (in line with Welsh Blood Transfusion guidelines)
- Recent transfusion, transplant, or skin graft
- Risk factors for variant Creutzfeldt-Jakob disease, e.g. blood transfusion or transplant after 1 January 1980

# Interventions

# Experimental arm

• FMT administered by retention enema either once only (group 1) or on 5 consecutive days (group 2)

# Control arm

• Bowel purgatives and antibiotic preparation without active administration of FMT (group 3)

# Outcomes

# Primary outcomes

- Remission of UC (mucosal healing; Mayo score ≤ 2 with Endoscopic Mayo score of 0) at week 12, as assessed by sigmoidoscopy, participants' response, Mayo scoring system
- Successful engraftment of donor fecal microbiota at week 12 as analyzed by 16S sequencing

# Secondary outcomes

- Rate of recruitment of participants
- Disease-specific severity scoring after treatment
- Histologic grading of colitis severity after treatment
- Mucosal immunologic response to treatment
- Rate of development of adverse effects of FMT

# Notes

Protocol article available

Study results available in an abstract but insufficient details to include study in analysis.

NCT02272868

# Methods

RCT conducted in the US

# Participants

# Inclusion criteria

- Children and adolescents ages 12–21 years
- Diagnosis of CD by primary gastroenterologist, based on history, physical exam, laboratory/radiologic studies and gastrointestinal histology
- Mild or moderate disease activity, based on PCDAI score (15–45)
- Ability of parent/guardian and child participant to comprehend consent and assent in English; and to attend study visits at baseline, and weeks 2, 6, and 12
- No changes in IBD medications for ≥ 1 month prior to enrollment

# Fecal transplantation for treatment of inflammatory bowel disease (Review)

Copyright © 2023 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.